CN106999534A - 用于治疗急性辐射综合症的组合物和方法 - Google Patents

用于治疗急性辐射综合症的组合物和方法 Download PDF

Info

Publication number
CN106999534A
CN106999534A CN201580061796.4A CN201580061796A CN106999534A CN 106999534 A CN106999534 A CN 106999534A CN 201580061796 A CN201580061796 A CN 201580061796A CN 106999534 A CN106999534 A CN 106999534A
Authority
CN
China
Prior art keywords
seq
pif
cells
pif peptide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580061796.4A
Other languages
English (en)
Chinese (zh)
Inventor
伊藤·R·巴尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioIncept LLC
Original Assignee
BioIncept LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioIncept LLC filed Critical BioIncept LLC
Publication of CN106999534A publication Critical patent/CN106999534A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
CN201580061796.4A 2014-09-16 2015-09-16 用于治疗急性辐射综合症的组合物和方法 Pending CN106999534A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462051077P 2014-09-16 2014-09-16
US62/051,077 2014-09-16
US201562113298P 2015-02-06 2015-02-06
US62/113,298 2015-02-06
US201562211660P 2015-08-28 2015-08-28
US62/211,660 2015-08-28
PCT/US2015/050532 WO2016044493A1 (en) 2014-09-16 2015-09-16 Compositions and methods for treating acute radiation syndrome

Publications (1)

Publication Number Publication Date
CN106999534A true CN106999534A (zh) 2017-08-01

Family

ID=55533820

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580061796.4A Pending CN106999534A (zh) 2014-09-16 2015-09-16 用于治疗急性辐射综合症的组合物和方法

Country Status (8)

Country Link
US (3) US20170319645A1 (enExample)
EP (1) EP3193903A4 (enExample)
JP (2) JP6806685B2 (enExample)
CN (1) CN106999534A (enExample)
AU (3) AU2015317771A1 (enExample)
CA (1) CA2961375A1 (enExample)
IL (2) IL295025A (enExample)
WO (1) WO2016044493A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3341739A4 (en) 2015-08-28 2019-07-10 BioIncept LLC MUTATED PEPTIDES AND METHOD FOR TREATING SUBJECTS THEREWITH
AU2016317574A1 (en) 2015-08-28 2018-03-29 Bioincept, Llc Compositions and methods for the treatment of neurodamage
EP3585420A4 (en) * 2017-02-22 2021-04-07 Bioincept LLC PEPTIDES AND METHODS OF TREATMENT OF DYSTROPHY RELATED CONDITIONS USING THEM
US20200246424A1 (en) * 2017-07-17 2020-08-06 Bioincept, Llc Peptides and methods of transplantation and restorative organ function
WO2022047196A1 (en) * 2020-08-28 2022-03-03 Nisibis, Llc-S Pten inhibitors for treatment and prevention of bone marrow loss
EP4408175A4 (en) * 2021-10-01 2025-08-06 Univ Colorado Regents COMPOSITIONS AND METHODS FOR REDUCED TOXICITY IN TRANSPLANTATION USING JANUS KINASE (JAK) INHIBITORS
EP4248985A1 (en) * 2022-03-25 2023-09-27 Consejo Superior de Investigaciones Científicas (CSIC) Peptides for the treatment of retinitis pigmentosa
WO2025117717A1 (en) * 2023-11-27 2025-06-05 The Brigham And Women’S Hospital, Inc. Skin based test for detection of radiation exposure

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040196A2 (en) * 2003-10-22 2005-05-06 Bioincept, Llc Pif peptides biologic activities, site of action, and the antibody to detect pif
US20110112016A1 (en) * 2004-10-22 2011-05-12 Biolncept, Llc Compositions and methods for modulating the immune system
WO2012119072A2 (en) * 2011-03-02 2012-09-07 Bioincept, Llc Compositions and methods for treatment of intracellular damage
WO2015061483A2 (en) * 2013-10-22 2015-04-30 Bioincept, Llc Pif-transfected cells and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4629722A (en) * 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
WO2013106273A2 (en) * 2012-01-09 2013-07-18 Serpin Pharma, Llc Peptides and methods of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040196A2 (en) * 2003-10-22 2005-05-06 Bioincept, Llc Pif peptides biologic activities, site of action, and the antibody to detect pif
US20110112016A1 (en) * 2004-10-22 2011-05-12 Biolncept, Llc Compositions and methods for modulating the immune system
WO2012119072A2 (en) * 2011-03-02 2012-09-07 Bioincept, Llc Compositions and methods for treatment of intracellular damage
WO2015061483A2 (en) * 2013-10-22 2015-04-30 Bioincept, Llc Pif-transfected cells and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
REUT SHAINER ET AL.: ""Immune Regulation and Oxidative Stress Reduction by Preimplantation Factor following Syngeneic or Allogeneic Bone Marrow Transplantation"", 《CONFERENCE PAPERS IN MEDICINE》 *
REUT SHAINER ET AL。: ""Preimplantation Factor (PIF) therapy provides comprehensive protection against radiation induced pathologies"", 《ONCOTARGET》 *
YEHUDITH AZAR ET AL.: ""Premplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative sresss(Murine Model)"", 《BIOLOGY OF BLOOD MARROW TRANSPLANT》 *

Also Published As

Publication number Publication date
JP6806685B2 (ja) 2021-01-06
EP3193903A4 (en) 2018-03-14
AU2015317771A1 (en) 2017-04-06
US20220249595A1 (en) 2022-08-11
US12458681B2 (en) 2025-11-04
IL295025A (en) 2022-09-01
US20240350580A1 (en) 2024-10-24
JP2017529396A (ja) 2017-10-05
WO2016044493A1 (en) 2016-03-24
US20170319645A1 (en) 2017-11-09
AU2021202310A1 (en) 2021-05-20
JP2021046432A (ja) 2021-03-25
CA2961375A1 (en) 2016-03-24
IL251108A0 (en) 2017-04-30
IL251108B (en) 2022-08-01
AU2019202741A1 (en) 2019-05-16
EP3193903A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
US12458681B2 (en) Compositions and method for treating acute radiation syndrome
US12285460B2 (en) Pharmaceutical compositions
US20250152665A1 (en) Mutant Peptides And Methods Of Treating Subjects Using The Same
EP3377085A1 (en) Peptides and methods of treating endometriosis using the same
Ma et al. Immunosuppressive effect of compound K on islet transplantation in an STZ-induced diabetic mouse model
DK2007416T3 (en) PARATYROIDEAHORMON (PTH) TO USE IN THE TREATMENT OF ICE CREAM
US10086070B2 (en) Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
CA2691415A1 (en) Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
Iannitti et al. Clinical use of immunosuppressants in Duchenne muscular dystrophy
KR20190096379A (ko) Ilc2 세포와 연관된 질환을 치료하는 방법
EP4066850A2 (en) Peptides and methods of treating dystrophy-related disorders using the same
WO2023230593A1 (en) Ptp1b inhibitors for treating lung injury
RU2844779C2 (ru) Фармацевтические композиции
HK40046859A (en) Pharmaceutical compositions
Badiwala et al. 489: Cilostazol as an Adjunct to Cyclosporine Prevents Neointimal Hyperplasia after Vascular Injury

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170801